Skip to main content
Clinical Trials/NCT04629300
NCT04629300
Completed
N/A

Randomized Trial of a Supportive Care Mobile Application to Improve Symptoms, Coping, and Quality of Life in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Massachusetts General Hospital6 sites in 1 country120 target enrollmentOctober 15, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Non Small Cell Lung Cancer
Sponsor
Massachusetts General Hospital
Enrollment
120
Locations
6
Primary Endpoint
Study feasibility based on rates of participant recruitment and completion of assigned study procedures
Status
Completed
Last Updated
last year

Overview

Brief Summary

This research study is looking at the role of a supportive care mobile app in improving symptoms, coping skills, and quality of life in patients with non-small cell lung cancer.

Detailed Description

This research study is a Feasibility Study, which is the first-time investigators are examining this supportive care mobile app intervention. The goal of this research study is to refine and examine the feasibility and benefits of a supportive care mobile app to improve symptoms, coping skills, and quality of life in patients with non-small cell lung cancer. Many people diagnosed with lung cancer experience challenging symptoms and increased stress. To help address these concerns, this study is exploring how a mobile application (app) intervention, designed specifically for people with lung cancer, can expand the availability of much needed supportive care services. The research study procedures include: * A supportive care mobile app consisting of six intervention modules that focus on components of wellbeing, such as physical, social, functional, and emotional wellbeing * Questionnaires asking about demographic information (e.g., gender, ethnicity, income) and participants' experience with cancer (e.g., quality of life, symptoms) * Data collection from participants medical records After completing a baseline study questionnaire, participants will be randomized into two (2) study groups: * Usual Care Group: Participants will receive standard oncology care and attend their regular clinic visits. Study staff will monitor participant use of supportive care services. * Intervention Group: Participants will be provided with a study-issued tablet computer to access the mobile app and receive tutorial and instructions for how to use the app. Participants will be in this research study for 12-14 weeks. It is expected that about 120 people will take part in this research study. The sponsors of this study are the National Comprehensive Cancer Network (NCCN) and AstraZeneca Pharmaceuticals. NCCN is a non-profit alliance of leading cancer centers across the United States, and AstraZeneca Pharmaceuticals is a global bio-pharmaceutical company. These two sponsors are together providing funding and oversight for the conduct of this research study.

Registry
clinicaltrials.gov
Start Date
October 15, 2021
End Date
July 31, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Joseph A. Greer, Ph.D.

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Age \>18 years
  • Diagnosed with unresectable Stage III or IV NSCLC in the past twelve weeks and receiving care with palliative intent (per clinician documentation in the electronic health record)
  • Eastern Cooperative Oncology Group Performance Status = 0-3
  • Plan to receive oncology care at one of the participating study sites
  • Ability to read and respond to questions in English

Exclusion Criteria

  • Significant uncontrolled psychiatric disorder (e.g., psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (e.g., dementia, cognitive impairment), which the treating oncology clinician reports would prohibit the ability to participate in study procedures

Outcomes

Primary Outcomes

Study feasibility based on rates of participant recruitment and completion of assigned study procedures

Time Frame: 12 weeks

Study feasibility will be defined as ≥ 65% approach-to-enrollment rate of eligible participants and ≥70% completion rate of study procedures (at least four mobile app modules and assigned study questionnaires)

Secondary Outcomes

  • Compare patient-reported coping between study groups on the Brief COPE Scale(12 weeks)
  • Compare patient-reported quality of life between study groups on the Functional Assessment of Cancer Therapy-Lung Scale(12 weeks)
  • Compare patient-reported psychological distress between study groups on the Hospital Anxiety and Depression Scale(12 weeks)
  • Patient-reported acceptability and usability of the mobile application intervention on the System Usability Scale(12 weeks)
  • Compare patient-reported symptoms between study groups on the MD Anderson Symptom Inventory(12 weeks)

Study Sites (6)

Loading locations...

Similar Trials